Graft Versus Host Disease (GvHD) Treatments
Find Graft Versus Host Disease (GvHD) Treatments
Brand Name
Ryoncil
Generic Name
Remestemcel-L-rknd
View Brand Information FDA approval date: March 17, 2025
Form: Kit
What is Ryoncil (Remestemcel-L-rknd)?
RYONCIL is indicated for the treatment of steroid refractory acute graft versus host disease in pediatric patients 2 months of age and older. RYONCIL is an allogeneic bone marrow-derived mesenchymal stromal cell therapy indicated for the treatment of steroid-refractory acute graft versus host disease in pediatric patients 2 months of age and older.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Tired of the same old research?
Related Clinical Trials
There is no clinical trials being done for this treatment